Federal Circuit Upholds Ruling Delaying Biosimilar Competition for Regeneron’s Eylea

The Federal Circuit has affirmed a decision permitting a West Virginia federal judge to supervise patent infringement litigation concerning biosimilars of Regeneron Pharmaceuticals’ Eylea, a popular treatment for eye diseases. This ruling empowers the judge to prevent pharmaceutical companies from South Korea and Germany from launching their biosimilar versions, maintaining the exclusivity of Regeneron’s product on the market. For further insights into this legal development, visit the detailed report by Law360.